Uganda

The National Drug Authority (NDA), established under the National Drug Policy and Authority Act (Cap. 206) of 1993 and its subsequent amendments, is the primary regulatory body responsible for overseeing the registration, quality assurance, and market authorization of health products in Uganda, including pharmaceuticals, medical devices, diagnostics, and increasingly digital health solutions. The NDA operates under the Ministry of Health and conducts product evaluations through its technical committees, requiring applicants to submit a formal registration dossier before any health product can be legally marketed or distributed in the country. The general approval process involves a scientific review of safety, efficacy, and quality data, followed by inspection of manufacturing facilities where applicable, and culminates in the issuance of a Marketing Authorization valid for a defined period, typically five years, subject to renewal.

Applicants must appoint a local authorized representative or agent registered with the NDA to submit and manage product dossiers on behalf of foreign manufacturers. The NDA accepts dossiers compiled in accordance with the Common Technical Document (CTD) format, and aligns progressively with the African Union's African Medicines Regulatory Harmonization (AMRH) framework and the East African Community (EAC) harmonized guidelines. Uganda is also a participating member of the African Medicines Agency (AMA) initiative, which aims to streamline regional approvals. Key submission requirements include Certificate of Pharmaceutical Product (CPP) from the country of manufacture, Good Manufacturing Practice (GMP) certificates, stability data relevant to climatic Zone IVb conditions, and labeling compliant with NDA standards. Recent reforms have focused on reducing registration backlogs, introducing risk-based classification for medical devices, expanding post-market surveillance capacity, and piloting expedited review pathways for priority health products addressing significant public health needs.

Public procurement of health products in Uganda is primarily coordinated through the Ministry of Health (MoH), with the National Medical Stores (NMS) serving as the central procurement and distribution agency responsible for sourcing and supplying medicines, medical devices, diagnostics, and other health commodities to government health facilities across the country. The Public Procurement and Disposal of Public Assets Authority (PPDA) governs the broader public procurement regulatory framework, establishing rules for tendering, contracting, and supplier prequalification. Health facilities at the district and facility level may also procure certain commodities through the Joint Medical Store (JMS), a non-governmental not-for-profit organization that supplements government supply channels. Procurement decisions at the central level are guided by the Uganda National Essential Medicines List (NEML) and corresponding treatment guidelines, which determine which products are eligible for public funding and institutional procurement.

Donor-funded and private sector channels play a substantial and complementary role in Uganda's health product market. Major multilateral and bilateral donors, including the Global Fund to Fight AIDS, Tuberculosis and Malaria, USAID through its global health procurement mechanisms such as GHSC-PSM, UNICEF Supply Division, and Gavi, the Vaccine Alliance, contribute significantly to the financing and direct procurement of health commodities, particularly for HIV, malaria, tuberculosis, immunization, and reproductive health programs. These donors often follow their own procurement and quality assurance standards, including WHO prequalification, which can serve as a pathway to market entry alongside or prior to full NDA registration. The private commercial sector, served by a network of pharmaceutical importers, distributors, and retail pharmacies, represents a growing procurement channel. Uganda does not currently enforce strong mandatory local manufacturing preference policies, but national strategies under the Uganda National Pharmaceutical Policy encourage local production, and regional EAC frameworks promote consideration of locally manufactured products as part of broader health security and import substitution objectives.